Phase 1/2Data readout

CNTY-101

B-Cell-Mediated Autoimmune Diseases

IPSCCentury Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: CNTY-101
Development stage: Phase 1/2
Event type: Data readout
Indication: B-Cell-Mediated Autoimmune Diseases

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for CNTY-101 in B-Cell-Mediated Autoimmune Diseases. The expected timing is based on the latest available company guidance and may change.

Development notes

11/13/25:- CARAMEL Ph1/2 IST treating B-cell autoimmune diseases; initial CNTY-101 data expected December 5, 2025. 03/12/26:- Ongoing CARAMEL Ph1/2 IST; updated preliminary CNTY-101 clinical data anticipated during 2026. 05/13/26:- PR No update. 08/12/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided